Evidence map›Paper›PMID 38457090›Full record

ArticleJournal of neuro-oncology2024

The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study.

Vincenzo Di Nunno, Giuseppe Lombardi, Matteo Simonelli, Giuseppe Minniti, Angela Mastronuzzi, Valentina Di Ruscio, Martina Corrà, Marta Padovan, Marta Maccari, Mario Caccese and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 1 country.

Vincenzo Di NunnoNervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, 40139, Italy.ORCID http://orcid.org/0000-0003-4441-9834
Giuseppe LombardiDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Matteo SimonelliDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy.
Giuseppe MinnitiDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Policlinico Umberto I, Rome, Italy.
Angela MastronuzziOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Valentina Di RuscioOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Martina CorràDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Marta PadovanDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Marta MaccariDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Mario CacceseDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Giorgia SimonettiNeuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Arianna BerlendisUnit of Immunotherapy of Brain Tumors, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, 20133, Italy.
Mariangela FarinottiUnit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, 20133, Italy.
Bianca PolloUnit of Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, 20133, Italy.
Manila AntonelliDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Policlinico Umberto I, Rome, Italy.
Antonio Di MuzioIRCCS Humanitas Research Hospital, Rozzano, Milano, Italy.
Angelo DipasqualeIRCCS Humanitas Research Hospital, Rozzano, Milano, Italy.
Sofia AsioliIRCCS-Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Dario De BiaseDepartment of Pharmacy and Biotechnology (FaBit), University of Bologna, Bologna, Italy.
Alicia TosoniNervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, 40139, Italy.
Antonio SilvaniNeuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Enrico FranceschiNervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, 40139, Italy. e.franceschi@isnb.it.
Fondazione IRCCS Istituto Neurologico Carlo Besta · ITIstituto Oncologico Veneto · ITIstituto delle Scienze Neurologiche di Bologna · ITBambino Gesù Children's Hospital · ITIRCCS Humanitas Research Hospital · ITPoliclinico Umberto I · ITAzienda USL di Bologna · ITHumanitas University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAdult Diffuse midline glioma (DMG) is a very rare disease. DMGs are currently treated with radiotherapy and chemotherapy even if only a few retrospective studies assessed the impact on overall survival (OS) of these approaches.

methodsWe carried out an Italian multicentric retrospective study of adult patients with H3K27-altered DMG to assess the effective role of systemic therapy in the treatment landscape of this rare tumor type.

resultsWe evaluated 49 patients from 6 Institutions. The median age was 37.3 years (range 20.1-68.3). Most patients received biopsy as primary approach (n = 30, 61.2%) and radiation therapy after surgery (n = 39, 79.6%). 25 (51.0%) of patients received concurrent chemotherapy and 26 (53.1%) patients received adjuvant temozolomide. In univariate analysis, concurrent chemotherapy did not result in OS improvement while adjuvant temozolomide was associated with longer OS (21.2 vs. 9.0 months, HR 0.14, 0.05-0.41, p < 0.001). Multivariate analysis confirmed the role of adjuvant chemotherapy (HR 0.1, 95%CI: 0.03-0.34, p = 0.003). In patients who progressed after radiation and/or chemotherapy the administration of a second-line systemic treatment had a significantly favorable impact on survival (8.0 vs. 3.2 months, HR 0.2, 95%CI 0.1-0.65, p = 0.004).

conclusionIn our series, adjuvant treatment after radiotherapy can be useful in improving OS of patients with H3K27-altered DMG. When feasible another systemic treatment after treatment progression could be proposed.

Indexed as

Brain NeoplasmsGliomaAdultAgedAntineoplastic Agents, AlkylatingChemotherapy, AdjuvantDacarbazineHumansMiddle AgedRetrospective StudiesTemozolomideYoung AdultAntineoplastic Agents, AlkylatingDacarbazineTemozolomideAdjuvant treatmentAdult DMGConcomitant chemotherapyDiffuse midline gliomaDMGH3K27 altered gliomaRadiotherapy

Identifiers

PMID38457090
OpenAlexW4392595614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.